NEXGEL (NXGL) Planet MicroCap Showcase: VEGAS 2025 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Showcase: VEGAS 2025 summary
3 Feb, 2026Business overview and growth strategy
Operates in three divisions: consumer products, contract manufacturing, and medical devices, with a focus on hydrogel technology for medical and cosmetic applications.
Expanded customer base includes major healthcare and consumer companies, fueling over 100% year-over-year growth for the past three years.
Facility in Pennsylvania features a rare electron beam accelerator for hydrogel production; packaging operations expanded in Texas with a new clean room.
Strategic partnerships and acquisitions, such as Kenkoderm and Silly George, have driven product and revenue diversification.
No company debt, with a focus on reducing cash burn and approaching EBITDA positive status.
Product innovation and pipeline
Medical device pipeline includes time-release drug patches and a human trial for an Apremilast patch targeting stubborn psoriasis lesions.
Consumer brands include MediGel, Kenkoderm (expanding to eczema products), and Silly George (eyelash and beauty products), with significant sales growth and new product launches planned.
SilverSeal, an antimicrobial wound and burn product, is now distributed through Cintas, increasing brand recognition and recurring revenue.
Partnership with STADA has exceeded projections, with new product launches and a growing U.S. platform.
Supplying gel pads for AbbVie's RESONIC cellulite treatment, with future revenue potential as the product launches.
Market positioning and competitive advantages
High water content, biocompatible hydrogels differentiate the company from competitors, making it the default choice for sensitive skin and medical applications.
U.S. manufacturing and tariff changes have made products more competitive against foreign UV gel manufacturers.
Custom and white label manufacturing offers expansion opportunities for partners in dermatology, beauty, and drug delivery markets.
Ongoing studies and commercial orders for gels used in laser hair removal and carcinogenic plume reduction, with potential for broader applications.
Marketing strategies are platform-specific, leveraging in-house analytics and external agencies to optimize direct-to-consumer sales.
Latest events from NEXGEL
- Record Q2 revenue and strong outlook driven by branded products and Silly George growth.NXGL
Q2 20242 Feb 2026 - Q3 revenue up 141% to $2.94M, gross margin 43.6%, but losses and risks persist.NXGL
Q3 202414 Jan 2026 - Strong growth from product innovation, acquisitions, and major partnerships, with profitability in focus.NXGL
IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 202411 Jan 2026 - Record revenue growth and improved margins set stage for positive EBITDA in 2025.NXGL
Q4 202424 Dec 2025 - Shareholders will vote on director elections, incentive plan expansion, and executive pay, all backed by the Board.NXGL
Proxy Filing2 Dec 2025 - Vote to increase authorized common stock to 1B shares for future flexibility is recommended.NXGL
Proxy Filing2 Dec 2025 - Q1 2025 revenue up 121%, margin at 42.4%, and positive EBITDA targeted for 2025.NXGL
Q1 202527 Nov 2025 - Q2 2025 revenue doubled and margins improved, but going concern risks persist.NXGL
Q2 202523 Nov 2025 - Q3 revenue steady at $2.93M, gross margin up, nine-month revenue up 52.7%, risks persist.NXGL
Q3 202517 Nov 2025